Appetite can feel different after the first few months of treatment. If you've noticed a change, a recent study offers a reason to look beyond the simple question of whether a medicine is “working.”
Researchers followed adults taking semaglutide or placebo for 60 weeks and measured several things separately: what people ate at a laboratory lunch, how they described their appetite, and how they responded to food-related cues. The results didn't all move in the same way.
Who took part?
The study randomly assigned 120 adults with overweight or obesity to weekly injectable semaglutide or a matching placebo. Seventy-two were assigned to semaglutide and 48 to placebo. Participants also received individual lifestyle counseling. The researchers assessed outcomes at the beginning and at weeks 20, 40, and 60.
It was a single-center study, and participants had to meet specific health criteria. People with type 1 or type 2 diabetes, for example, were not included. Most participants were women, and most identified as White. The group gives researchers useful information, but it doesn't represent every person who might use a weight-management medicine.
The study received partial support from a Novo Nordisk research grant. The authors reported that the company did not take part in the study's conception, conduct, analysis, or reporting. That funding information belongs alongside the methods when evaluating the results.
What happened at the lunch?
At each assessment, participants were offered a laboratory lunch and could eat as much as they wanted. The researchers measured the change in energy intake from the starting visit. This was the study's main outcome.
Compared with the placebo group, the semaglutide group showed a greater average reduction in intake at the laboratory lunch at all three follow-up assessments. The group-level difference remained at week 60, even though the size and pattern of changes varied over time.
That lunch was a standardized research measurement, not a complete record of everything someone ate at home. It can't tell an individual how much to eat or establish that a particular daily calorie change will occur. It also doesn't tell us whether every participant experienced the same effect.
Appetite was measured another way
The researchers asked participants to rate feelings such as hunger and fullness around a standardized breakfast. They also asked about experiences over the previous week, including hunger and preoccupation with food.
At week 20, the semaglutide group reported greater average improvements than placebo on several appetite measures, including past-week hunger and food preoccupation. At weeks 40 and 60, the differences between groups were smaller and were not statistically significant for those particular appetite measures.
That's a nuanced result. It doesn't prove that the groups had identical experiences later, and it doesn't mean every person became hungrier. It means this study did not establish a clear between-group difference on those measures at those later time points. Participants' own experiences varied.
The researchers also found that changes in past-week fullness after meals did not differ significantly between the groups at any assessment. “Appetite” covers several experiences, and they don't necessarily change together.
What is “food reward” in this context?
The study used questionnaires and tasks to explore different aspects of how participants responded to food. One questionnaire asked about responsiveness to the rewarding value of food. Another task examined measures of wanting particular food categories.
Compared with placebo, the semaglutide group showed greater average reductions on one measure of food responsiveness at weeks 20 and 40, but the group difference did not reach statistical significance at week 60. For the measured wanting of high-fat savory foods, the changes did not differ significantly between groups at the assessments.
These tools are specific research measures. They aren't a direct test of whether a person enjoys food, and they shouldn't be treated as a score for someone reading the article. A questionnaire about food preoccupation may overlap with what people casually call “food noise,” but the terms aren't automatically interchangeable.
What limits the conclusion?
Not everyone completed every assessment. About 73% of all participants completed the week-60 assessments, and more participants in the placebo group were lost to follow-up or withdrew. Missing information matters because the people who remain may differ from those who leave. The researchers used statistical methods to account for missing data, but those methods rely on assumptions.
The study also measured a particular injectable dose and a particular counseling program. It cannot establish what happens with every formulation, every dose, or every combination of treatment and support. Later appetite ratings and one laboratory meal are pieces of evidence, not a complete explanation of weight change.
If your appetite changes over time
An experience doesn't have to match a study average to be worth discussing. If hunger feels different from when you started, tell your prescriber what changed and whether your meals, side effects, or routine have changed too. You can also ask a dietitian for help finding meals that are satisfying and adequate for you.
Don't change your prescribed dose based on a headline or try to recreate a laboratory meal. If you're struggling to eat enough, experiencing persistent nausea, or having another concerning symptom, contact your care team.
This study's most useful lesson may be that eating, hunger, fullness, and food reward are related but distinct. A single feeling on a single day doesn't tell the whole story.










